Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 5, 2000, Pages 417-422

  Finlay, Graeme J ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Albumin; Cytotoxic drugs; Acid glycoprotein

Indexed keywords

ACRIDINE DERIVATIVE; AMSACRINE; ANTINEOPLASTIC AGENT; ASULACRINE ISETHIONATE; CAMPTOTHECIN; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; OROSOMUCOID; PACLITAXEL; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; IN VITRO STUDY; LEWIS CARCINOMA; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034047105     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051011     Document Type: Article

References (37)

1. 1. Arlin ZA (1989) A special role for amsacrine in the treatment of acute leukemia. Cancer Invest 7: 607
2. 2. Atwell GJ, Cain BF, Baguley BC, Finlay GJ, Denny WA (1984) Potential antitumor agents. Part 43. Synthesis and biological activity of dibasic 4-carboxamido-9-aminoacridines, a new class of antitumor agent. J Med Chem 27: 1481
3. 3. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664
4. 4. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)-phenylamino]-4-acridinecarboxamide. Cancer Res 44: 3245
5. 5. Bridewell DJA, Finlay GJ, Baguley BC (1999) Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II. Cancer Chemother Pharmacol 43: 302
6. 6. Cain BF, Atwell GJ, Denny WA (1975) Potential antitumor agents. Part 16. 4′-(Acridin-9-ylamino)methanesulfonanilides. J Med Chem 18: 1110
7. 7. Chabot GG (1994) Factors involved in clinical pharmacology variability in oncology. Anticancer Res 14: 2269
8. 8. Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP (1996) Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 38: 571
9. 9. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73
10. 10. Creaven PJ, Allen LM, Muggia FM (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573
11. 11. de Lannoy IA, Mandin RS, Silverman M (1994) Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharm Exp Ther 268: 388
12. 12. Denny WA, Atwell GJ, Rewcastle GW, Baguley BC (1987) Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid tumor activity. J Med Chem 30: 658
13. 13. Eksborg S, Ehrsson H, Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to Adriamycin. Cancer Chemother Pharmacol 10: 7
14. 14. Evans SMH, Robertson IGC, Paxton JW (1994) Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J Pharm Pharmacol 46: 63
15. 15. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401
16. 16. Finlay GJ, Riou J-F, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32 A: 708
17. 17. Fleming RA, Evans WE, Arbuck SG, Stewart CF (1992) Factors affecting in vitro protein binding of etoposide in humans. J Pharm Sci 81: 259
18. 18. Graham MA, Kaye SB (1993) New approaches in preclinical and clinical pharmacokinetics. Cancer Surv 17: 27
19. 19. Hardy JR, Harvey VJ, Paxton JW, Evans PC, Smith S, Grillo-Lopez A, Grove W, Baguley BC (1988) A phase I trial of the amsacrine analog 9-[[2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide (CI-921). Cancer Res 48: 6593
20. 20. Hu OY, Chang SP, Law CK, Jian JM, Chen KY (1992) Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer 69: 847
21. 21. Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IGC, Baguley BC (1990) Disposition of amsacrine and its analogue 9-((2-methoxy-4-[(methylsulfonyl)-amino]phenyl)-amino)-N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res 50: 503
22. 22. Kestell P, Dunlop I, McCrystal MR, Evans BD, Paxton JW, Gamage RSKA, Baguley BC (1999) Plasma pharmacokinetics of N-[2-(dimethylamino)-ethyl]-acridine-4-carboxamide (DACA) in a phase I trial. Cancer Chemother Pharmacol 44: 45
23. 23. Kremer JM, Wilting J, Janssen LH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40: 1
24. 24. Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Binding of Taxol to human plasma, albumin and alpha-1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80: 337
25. 25. Liu B, Earl HM, Poole CJ, Dunn J, Kerr DJ (1995) Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 36: 506
26. 26. McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agent N-[2-dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44: 39
27. 27. Mi Z, Burke TG (1994) Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33: 12540
28. 1-acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol 5: 635
29. 29. Paxton JW, Jurlina JL, Foote SE (1986) The binding of amsacrine to human plasma proteins. J Pharm Pharmacol 38: 432
30. 30. Paxton JW, Hardy JR, Evans PC, Harvey VJ, Baguley BC (1988) The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfhonylamino)phenylamino]-4-acridine carboxamide (CI-921) in a phase I trial. Cancer Chemother Pharmacol 22: 235
31. 31. Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE (1992) Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy 12: 273
32. 32. Raveendran R, Heybroek WM, Caulfield M, Abrams SML, Wrigley PFM, Slevin M, Turner P (1992) Protein binding of indomethacin, methotrexate and morphine in patients with cancer. Int J Clin Pharmacol Res 12: 117
33. 33. Rewcastle GW, Atwell GJ, Chambers D, Baguley BC, Denny WA (1986) Potential antitumor agents. 46. Structure-activity relationships for acridine mono-substituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. J Med Chem 29: 472
34. 34. Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacdokinet 27: 256
35. 35. Spicer JA, Gamage SA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA (1997) Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 40: 1919
36. 36. Urien S, Bree F, Testa B, Tillement JP (1991) pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J 280: 277
37. 37. Woodcock BG, Abdelrahman MS, Wosch F, Harder S (1993) Effect of D,L -verapamil, verapamil enantiomers and verapamil metabolites on the binding of vincristine to alphal-acid glycoprotein. Eur J Cancer 29 A: 559